Mondego Bio Initiates First-in-Human Study of MB‑388, an Oral Dual PTPN2/PTPN1 Inhibitor Designed to Overcome Resistance to Cancer Immunotherapy

The Quick Take
Phase 1a study in healthy volunteers will assess safety, pharmacokinetics and pathway engagement; Phase 1b study in patients with advanced solid tumors planned to begin in January 2027 CANTANHEDE, Portugal, Nov. 5, 2026 /PRNewswire/ -- Mondego Bio today announced the initiation of a...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Citizens raises Progyny stock price target on guidance increase
Business
Goldman Sachs lowers Timken stock price target to $126 on valuation
Business
Citizens raises Procore stock price target to $91 on strong results
Business
